Before you continue
To give you the best possible experience please select your preference.
To give you the best possible experience please select your preference.
Challenge: Bridging the information gap in RSV awareness
ReSViNET, a non-profit organisation committed to reducing the global effects of RSV (Respiratory Syncytial Virus) infections, sought an innovative solution to provide timely, accurate, and multilingual information to healthcare professionals, caregivers, patients and public worldwide. RSV can cause severe respiratory illness, particularly in vulnerable individuals such as infants, elderly or people with weakened immune systems, so access to trustworthy information on symptoms, treatment and immunization options is essential. But reaching a diverse, global audience – especially in remote and underserved regions – proved challenging due to language barriers and limited access to conventional communication channels like email, leaflets or static websites.
Solution: AI-driven RSV chatbot
To overcome these barriers, ReSViNET partnered with Enreach to develop a multilingual AI-powered chatbot capable of delivering instant and accurate answers on RSV-related topics, including the disease burden, prevention, treatment options and immunization availability. Target groups include parents, at-risk adults, and healthcare professionals.
The chatbot’s responses are based on a curated medical knowledge base, ensuring that all information is medically validated and up to date.
Key features include:
Multilingual Support: Using OpenAI’s models, the chatbot offers real-time responses in multiple languages, making it accessible to a global audience. User-centric accessibility: The chatbot is integrated into the ReSViNET website and WhatsApp, enabling users to access information through their preferred communication channels.
Context retention: The chatbot can remember user interactions, allowing for seamless follow-up and ongoing dialogues.
QR code integration: Hospitals and healthcare centres can distribute QR codes linking directly to the chatbot, so patients can ask for immediate assistance when needed.
Outcome: Expanded reach and improved engagement
Since its launch, the RSV chatbot has significantly improved access to trustworthy, medically validated RSV-related information, particularly in regions where digital infrastructure and access to medical expertise are limited. This innovative tool has introduced a new, scalable communication channel, reaching a wider and more diverse audience than ever before.
“Access to reliable and timely information is crucial in the fight against RSV. Through our partnership with Enreach, we have taken a major step forward with the launch of an AI-powered chatbot that bridges knowledge gaps and reaches those most in need of trustworthy information. By providing multilingual, medically sound insights in real-time, the chatbot empowers healthcare professionals, caregivers, and patients with everything they need to make informed decisions. Specifically, the chatbot helps parents throughout the world decide on RSV immunization by providing personalized information. This innovation not only improves accessibility but also builds trust and engagement—key elements in improving global RSV awareness and prevention.”
In addition to his role at ReSViNET, Prof. Dr. Louis Bont is Pediatric Infectious Diseases Specialist, Head of the Department of Pediatrics at Wilhelmina Children’s Hospital (UMCU), Netherlands, and Visiting Professor at Yale University, contributing to international RSV research collaborations.
Measurable impacts include:
Strong User Engagement: Since its launch on 12 November, the chatbot has engaged with 4,200 users. As a newly introduced channel, engagement levels have varied based on the intensity of internal promotional efforts. Rapid Information Delivery: ReSViNET has significantly reduced the time required to provide accurate medical information from hours or days (via traditional methods) to mere seconds through the chatbot.
Multilingual Accessibility: The chatbot provides medically sound information and responses in over 100 languages, eliminating language barriers for non-English-speaking users, enabling more inclusive and equitable access to essential RSV information.
Scalability and continuous improvement: The chatbot is continuously improved based on user interactions and is regularly updated, reflecting up-to-date information on RSV prevention, treatments and immunisations. To further expand its reach, plans are underway to grow engagement through targeted PR and social media campaigns, as well as collaboration with professional networks and health care organisations.
24/7 Availability and Empathetic Support: The chatbot’s round the clock presence, empowers patients and caregivers to ask all their questions at their own pace. The chatbot offers clear, comforting and empathetic responses. This ensures that no concern or question is left unaddressed, helping reduce anxiety and complementing the care provided by often overstretched healthcare professionals.
“At ReSViNET, we believe that equitable access to knowledge is a fundamental part of improving global health. Everyone, regardless of where they live or what language they speak, deserves timely, accurate, and understandable information about RSV. This chatbot is a powerful step toward breaking down barriers to that access. By leveraging technology in a thoughtful, human-centred way, we’re not only sharing medical knowledge but also building trust, empowering communities, and advancing health equity worldwide.”
About the customer
The ReSViNET Foundation is a globally recognized non-profit organisation dedicated to reducing the global burden of RSV infection. The foundation fosters international collaboration among researchers, healthcare professionals, policymakers, and civil society to promote research, raise awareness, and support the development of preventive and therapeutic solutions. ReSViNET focuses particularly on vulnerable populations such as infants, older adults, and individuals with compromised immunity—working to improve health outcomes through innovation, education, and advocacy.
This customer case was published in cooperation with Schmuki, a Digital and AI agency.
Austria
Denmark
Finland
France
Germany
Latvia
Netherlands
Spain
Sweden
Switzerland
United Kingdom
Global
